In a report released today, Jessica Fye from J.P. Morgan maintained a Buy rating on Alnylam Pharma, with a price target of $348.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Jessica Fye’s rating is based on the strong performance and future potential of Alnylam Pharma’s Amvuttra product in the ATTR-CM market. The company has shown impressive sales growth, with recent estimates for Amvuttra sales significantly surpassing previous expectations. This positive trend is supported by data analysis and market insights, suggesting a substantial opportunity for Amvuttra in treating TTR amyloidosis.
Additionally, Alnylam’s broad platform and promising pipeline contribute to a favorable outlook for the company. The firm’s strategic positioning in the ATTR-CM market, combined with its innovative product offerings, underpins the decision to raise the price target for Alnylam’s stock. These factors collectively justify the Buy rating, reflecting confidence in the company’s ability to capitalize on its market opportunities and deliver strong financial performance.
Fye covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Ascendis Pharma, and BioNTech SE. According to TipRanks, Fye has an average return of 6.9% and a 53.78% success rate on recommended stocks.
In another report released on July 14, Citi also maintained a Buy rating on the stock with a $404.00 price target.